Skip to main content
. Author manuscript; available in PMC: 2013 Nov 16.
Published in final edited form as: Immunity. 2012 Nov 8;37(5):800–812. doi: 10.1016/j.immuni.2012.08.019

Figure 5. IKKi-mediated inactivation of GSK3α is required for IL-1-induced AKT-mTOR activation.

Figure 5

(A) Cell lysates from wild-type and GSK3α KI(S21A) Th17 cells untreated or treated with IL-1 (10ng/ml) for different time points were analyzed by western blot analysis using antibodies as indicated. (B) Wild-type and GSK3α KI Th17 cells were rested for overnight, followed by incubation with 10ng/ml IL-1 or IL-2 for three additional days. The treated cells were incubated one additional day with 3H for thymidine incorporation experiment. (C) Naïve wild-type, GSK3α KI CD4+ T cells were polarized to Th17 cells in the presence and absence of IL-1β, followed by intracellular cytokine staining for IL-17 and IFN-γ (D) Real-time PCR analysis of relative expression of IL-17, IL-21, IL-23R, and ROR-γt in wild-type and GSK3α KI Th17 cells as compared to the Th0 cells. All data are representative of at least three separate experiments. Error bars (B and D), s.d. **, p<0.01 (two tailed t-test).